Vaxcyte Past Earnings Performance
Past criteria checks 0/6
Vaxcyte's earnings have been declining at an average annual rate of -44.3%, while the Biotechs industry saw earnings growing at 12.3% annually.
Key information
-44.3%
Earnings growth rate
37.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -32.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Dec 27
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
Sep 12Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation
May 30We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth
Dec 22Vaxcyte appoints new CBO, CMO
Oct 11Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Aug 05Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate
Jul 12Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Feb 25We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
Nov 08We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow
Jul 26We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow
Apr 12Revenue & Expenses BreakdownBeta
How Vaxcyte makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -402 | 61 | 332 |
| 30 Sep 23 | 0 | -300 | 55 | 280 |
| 30 Jun 23 | 0 | -265 | 50 | 230 |
| 31 Mar 23 | 0 | -245 | 45 | 196 |
| 31 Dec 22 | 0 | -223 | 40 | 169 |
| 30 Sep 22 | 0 | -174 | 35 | 141 |
| 30 Jun 22 | 0 | -143 | 30 | 114 |
| 31 Mar 22 | 0 | -118 | 27 | 93 |
| 31 Dec 21 | 0 | -100 | 25 | 78 |
| 30 Sep 21 | 0 | -92 | 23 | 70 |
| 30 Jun 21 | 0 | -87 | 22 | 66 |
| 31 Mar 21 | 0 | -83 | 19 | 67 |
| 31 Dec 20 | 0 | -89 | 16 | 74 |
| 30 Sep 20 | 0 | -83 | 14 | 72 |
| 30 Jun 20 | 0 | -73 | 11 | 66 |
| 31 Mar 20 | 0 | -64 | 11 | 57 |
| 31 Dec 19 | 0 | -50 | 9 | 46 |
| 31 Dec 18 | 0 | -29 | 5 | 30 |
Quality Earnings: PCVX is currently unprofitable.
Growing Profit Margin: PCVX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PCVX is unprofitable, and losses have increased over the past 5 years at a rate of 44.3% per year.
Accelerating Growth: Unable to compare PCVX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PCVX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: PCVX has a negative Return on Equity (-32.43%), as it is currently unprofitable.